Targeting NAD⁺ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance.

ABSTRACT: To improve therapeutic responses in patients with glioma, new combination therapies that exploit a mechanistic understanding of the inevitable emergence of drug resistance are needed. Intratumoral heterogeneity enables a low barrier to resistance in individual patients with glioma. We reasoned that targeting two or more fundamental processes that gliomas are particularly dependent upon could result in pleiotropic effects that would reduce the diversity of resistant subpopulations allowing convergence to a more robust therapeutic strategy. In contrast to the cytostatic responses observed with each drug alone, the combination of the histone deacetylase inhibitor panobinostat and the proteasome inhibitor bortezomib synergistically induced apoptosis of adult and pediatric glioma cell lines at

SUBMITTER: Jane EP 

PROVIDER: S-EPMC7335346 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature